Global Healthcare Study on Atopic Dermatitis

NCT07659756 | Recruiting

• 1 other identifier: 2024-01704-2
• Study Type: observational
• Target: 9,600
• Locations: 1 country
• Sites: 1

Brief Summary

The Global Healthcare Study on Atopic Dermatitis (GHSAD) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with atopic dermatitis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.

Conditions

Atopic Dermatitis (AD); Atopic Dermatitis (Eczema)

Keywords

Dermastudy; GHSAD; GHRSD

Outcome Measures

Primary Outcomes (1)

• Eczema Area and Severity Index (EASI)

  Clinician-assessed measure of atopic dermatitis severity based on extent and severity of eczema signs; total score ranges from 0 to 72, with higher scores indicating more severe disease.

  Baseline and follow-up visits every 6-12 months for up to 5 years.

Secondary Outcomes (7)

• SCORing Atopic Dermatitis (SCORAD)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Dermatology Life Quality Index (DLQI)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Patient-Oriented Eczema Measure (POEM)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Peak Pruritus Numerical Rating Scale (PP-NRS)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

• Physician Global Assessment (PGA)

  Baseline and follow-up visits every 6-12 months for up to 5 years.

Study Arms (1)

Global Healthcare Study on Atopic Dermatitis

Patients with Atopic Dermatitis

Eligibility Criteria

• Age: 14 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient populations across world regions seen for atopic dermatitis.

You may qualify if:

• Signed General Consent Form, or equivalent document
• Confirmed diagnosis of Atopic Dermatitis

You may not qualify if:

• Inability to provide informed consent.
• Datasets with ambiguous or unclear diagnosis.

Sponsors & Collaborators

• Julia Tatjana Maul: lead
• University of Zurich: collaborator
• University Hospital, Zürich: collaborator

Study Sites (1)

University of Zurich

Zurich, Switzerland

RECRUITING

MeSH Terms

Conditions

Dermatitis, Atopic; Eczema

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Julia-Tatjana Maul, Prof. Dr. med.

  University of Zurich

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Julia-Tatjana Maul, Prof. Dr. med.

CONTACT

+41 76 441 51 09; julia-tatjana.maul@usz.ch

Johannes Didaskalu

CONTACT

johannes.didaskalu@usz.ch

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 5 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Prof. Dr. med.

Study Record Dates

• First Submitted: June 15, 2026
• First Posted: June 22, 2026
• Study Start: January 1, 2025
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): December 31, 2029
• Last Updated: June 22, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)